Focused Update on Dual Antiplatelet Therapy (DAPT)

Publication Date: 2017

Chairperson: Marco Valgimigli & Héctor Bueno

Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dual antiplatelet therapy, Acute coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting stents, Myocardial infarction, Stent thrombosis, Bleeding, Percutaneous coronary intervention, Recommendation, Revascularization, Risk stratification, Stents, Stable angina, Stable coronary artery disease, Oral anticoagulant, Triple therapy, DAPT score, PRECISE-DAPT score, Non-cardiac surgery

Pocket Guidelines on the 2017 Focused Update on Dual Antiplatelet Therapy


2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)


The estimated number of patients requiring dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and an oral inhibitor of the platelet P2Y12 receptor for adenosine 5′-diphosphate (ADP), is considerable and has increased over time in Europe. Based on population estimates from 2015, in the region of 1 400 000 and 2 200 000 patients per year may have an indication for DAPT after coronary intervention or myocardial infarction (MI), respectively.